TABLE 1.

Methylation differences of S100P and HYAL2 between BC cases and controls in Study I.

CpG sites	Controls median (IQR)	BC cases median (IQR)	OR (95% CI)* per −10% methylation	p-value*
S100P_CpG_2.3	0.64 (0.60–0.67)	0.65 (0.62–0.69)	0.59 (0.38–0.91)	0.017
S100P_CpG_4	0.71 (0.67–0.75)	0.71 (0.68–0.76)	0.60 (0.42–0.84)	0.003
S100P_CpG_7	0.42 (0.35–0.48)	0.41 (0.35–0.47)	0.95 (0.78–1.16)	0.601
S100P_CpG_8	0.48 (0.43–0.53)	0.49 (0.42–0.56)	0.97 (0.77–1.23)	0.792
S100P_CpG_9	0.52 (0.43–0.58)	0.52 (0.44–0.61)	0.64 (0.48–0.85)	0.002
S100P_CpG_10.11.12	0.62 (0.58–0.65)	0.64 (0.60–0.68)	0.61 (0.44–0.84)	0.003
HYAL2_CpG_1	0.33 (0.29–0.37)	0.32 (0.28–0.37)	1.00 (0.73–1.37)	0.984
HYAL2_CpG_2	0.24 (0.19–0.28)	0.23 (0.18–0.29)	0.96 (0.73–1.24)	0.730
HYAL2_CpG_3	0.38 (0.34–0.41)	0.37 (0.32–0.41)	1.19 (0.83–1.71)	0.343
HYAL2_CpG_4	0.53 (0.49–0.58)	0.54 (0.48–0.58)	0.90 (0.68–1.20)	0.474

*Logistic regression, adjusted for age and batches of measurement. BC, breast cancer; S100P, S100 calcium-binding protein P gene; HYAL2, hyaluronoglucosaminidase 2 gene; OR, odds ratio; IQR, interquartile range. The bold values indicate p < 0.05.